CX 8184
Alternative Names: CX-8184Latest Information Update: 05 Apr 2024
At a glance
- Originator Cylene Pharmaceuticals
- Developer Cylene Pharmaceuticals; Senhwa Biosciences
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Casein kinase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Viral infections
- Discontinued Cancer